Compare DexCom, Inc. (DXCM) vs Iris Energy Limited (IREN) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

IREN is trading at $36.28, down 5.99% in the last session, amid a bearish technical outlook with selling pressure across moving averages. The company shows strong revenue growth projections, with 2026 revenue expected to reach $757 million and net profit margin improving to 20.87%. Recent executive appointments and AI infrastructure expansion signal strategic transformation, though the stock faces execution risks and negative profitability metrics.

The investment case hinges on IREN's successful pivot to AI cloud infrastructure, supported by analyst consensus of $79.11 price target and 71% buy ratings. However, negative ROE (-9.58%) and consecutive earnings misses present significant execution risks, while technical indicators suggest near-term pressure with support at $35.